Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 1
2006 1
2009 5
2010 7
2011 5
2012 3
2013 3
2014 7
2015 7
2016 8
2017 6
2018 10
2019 7
2020 16
2021 26
2022 30
2023 17
2024 23
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean n afzal (841 results)?
An update on periodontal inflammation and bone loss.
Zhang M, Liu Y, Afzali H, Graves DT. Zhang M, et al. Front Immunol. 2024 Jun 11;15:1385436. doi: 10.3389/fimmu.2024.1385436. eCollection 2024. Front Immunol. 2024. PMID: 38919613 Free PMC article. Review.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
FINDINGS: Between July 23, 2019, and Aug 23, 2023, 1150 patients were randomly assigned and received study treatment (safety population); 1065 patients were included in the efficacy population and received mirikizumab (n=579), ustekinumab (n=287), or placebo (n …
FINDINGS: Between July 23, 2019, and Aug 23, 2023, 1150 patients were randomly assigned and received study treatment (safety population); 10 …
Literature Commentary.
[No authors listed] [No authors listed] J Neuroophthalmol. 2023 Mar 1;43(1):e26-e36. doi: 10.1097/WNO.0000000000001813. Epub 2023 Jan 18. J Neuroophthalmol. 2023. PMID: 40418693
Ophthalmol Ther. 2022. doi: 10.1007/s40123-022-00611-x.Noll C, Hiltensperger M, Aly L, Wicklein R, Afzali AM, Mardin C, Gasperi C, Berthele A, Hemmer B, Korn T, Knier B. Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis. ... …
Ophthalmol Ther. 2022. doi: 10.1007/s40123-022-00611-x.Noll C, Hiltensperger M, Aly L, Wicklein R, Afzali AM, Mardin C, Gasperi C, Be …
Negative Pressure Dressings to Prevent Surgical Site Infection After Emergency Laparotomy: The SUNRRISE Randomized Clinical Trial.
SUNRRISE Trial Study Group; Atherton K, Brown J, Clouston H, Coe P, Duarte R, Dudi-Venkata NN, Duff S, Egoroff N, Fish R, Glasbey J, Ives N, Kaur M, Magill L, Mehta S, Pinkney T, Pockney P, Richards T, Sammour T, Sekhar H, Sinha Y, Stott M, Wilkin R. SUNRRISE Trial Study Group, et al. JAMA. 2025 Mar 11;333(10):853-863. doi: 10.1001/jama.2024.24764. JAMA. 2025. PMID: 39869330 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomized 1:1 to receive iNPWT (n = 411), which involved a specialized dressing used to create negative pressure over the closed wound vs the surgeon's choice of wound dressing (n = 410). ...Overall, 52% were female; the mean age wa …
INTERVENTIONS: Participants were randomized 1:1 to receive iNPWT (n = 411), which involved a specialized dressing used to create nega …
C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection.
Desai JV, Kumar D, Freiwald T, Chauss D, Johnson MD, Abers MS, Steinbrink JM, Perfect JR, Alexander B, Matzaraki V, Snarr BD, Zarakas MA, Oikonomou V, Silva LM, Shivarathri R, Beltran E, Demontel LN, Wang L, Lim JK, Launder D, Conti HR, Swamydas M, McClain MT, Moutsopoulos NM, Kazemian M, Netea MG, Kumar V, Köhl J, Kemper C, Afzali B, Lionakis MS. Desai JV, et al. Cell. 2023 Jun 22;186(13):2802-2822.e22. doi: 10.1016/j.cell.2023.04.031. Epub 2023 May 22. Cell. 2023. PMID: 37220746 Free PMC article.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
FINDINGS: Between June 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to receive ustekinumab (n=191) or adalimumab (n=195). 29 (15%) of 191 patients in the ustekinumab group and 46 (24%) of 195 in t …
FINDINGS: Between June 28, 2018, and Dec 12, 2019, 633 patients were assessed for eligibility and 386 were enrolled and randomly assigned to …
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Sandborn WJ, et al. Gastroenterology. 2022 May;162(6):1650-1664.e8. doi: 10.1053/j.gastro.2022.01.047. Epub 2022 Feb 5. Gastroenterology. 2022. PMID: 35134323 Free article. Clinical Trial.
BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells.
Yao C, Lou G, Sun HW, Zhu Z, Sun Y, Chen Z, Chauss D, Moseman EA, Cheng J, D'Antonio MA, Shi W, Shi J, Kometani K, Kurosaki T, Wherry EJ, Afzali B, Gattinoni L, Zhu Y, McGavern DB, O'Shea JJ, Schwartzberg PL, Wu T. Yao C, et al. Nat Immunol. 2021 Mar;22(3):370-380. doi: 10.1038/s41590-021-00868-7. Epub 2021 Feb 11. Nat Immunol. 2021. PMID: 33574619 Free PMC article.
172 results